COMMUNIQUÉS West-GlobeNewswire

Vistin Pharma ASA: Invitation to Q2 2026 conference call
13/08/2026
Oslo, Norway, 13 August 2026 Vistin Pharma ASA (VISTN) will release its second quarter and YTD 2026 results on Thursday 20th of August 2026. Vistin Pharma will host a conference call for all shareholders and other [...]
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
13/08/2026
Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and [...]
Valneva publie ses résultats financiers du premier semestre 2026 et fait un point sur ses activités
13/08/2026
Ventes totales de produits de 64,0 millions d’euros o En ligne avec les attentes ; confirmation de la prévision annuelle de ventes comprises entre 135 et 150 millions d’euros. Solide position de trésorerie de 121,5 [...]
Zealand Pharma Announces Financial Results for the First Half of 2026
13/08/2026
Company announcement – No. 39 / 2026 Zealand Pharma Announces Financial Results for the First Half of 2026 A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum [...]
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
13/08/2026
Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan [...]
Kuros Biosciences delivers 45% H1 2026 year-over-year sales growth and increases overall profitability
13/08/2026
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences delivers 45% H1 2026 year-over-year sales growth and increases overall profitability Schlieren (Zurich), Switzerland, August 13, 2026 [...]
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
13/08/2026
ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab- [...]
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
13/08/2026
U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) with Priority Review for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); Prescription Drug User Fee Act (PDUFA) target [...]
NOTICE TO DISREGARD -- Leading Edge Health Inc
13/08/2026
LAS VEGAS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- We are advised by VITALIBOOST LLC that journalists and other readers should disregard the news release, “Load Boost: Semenax, Volume Pills or SemEnhance - Which is Best Load [...]
NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership
12/08/2026
The Signed MOU Targets Initial GMP Exosome Batches in H1 2027 to Support NurExone’s Clinical Pipeline and Planned Commercial Production TORONTO and HAIFA, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc [...]
Park Dental Partners Announces Second Quarter 2026 Results
12/08/2026
MINNEAPOLIS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK) and affiliated dental practices (“Park Dental Partners,” “we,” “our,” “us,” or the “Company”) today reported its second quarter [...]
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
12/08/2026
- U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new [...]
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
12/08/2026
- Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program - Upfront proceeds [...]
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
12/08/2026
Completed enrollment for Cohort 1 (gluten challenge) of Phase 1b ANB033 trial in celiac disease (CeD); top-line Cohort 1 data reaffirmed for Q4 2026 Cohort 2 (mucosal healing) enhanced to enroll up to 40 patients [...]
BIO GREEN MED SOLUTION REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
12/08/2026
KUALA LUMPUR, MALAYSIA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; "BGMS" or the "Company"), a diversified company engaged primarily in the provision of fire safety protection and [...]
Range Impact Reports 2Q 2026 Financial Results
12/08/2026
CLEVELAND, OHIO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public company dedicated to acquiring, reclaiming, and redeveloping legacy coal mines throughout [...]
Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
12/08/2026
Company announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 [...]
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
12/08/2026
Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided 1L Consolidation Therapy [...]
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
12/08/2026
On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and [...]

Pages